Back to News
Market Impact: 0.2
Qurient Announces Publication in Science Advances Demonstrating Synergistic Effect of Selective CDK7 Inhibitor Q901 with TOP1 Inhibitor-Based ADCs
Source: Business Wire
Healthcare & BiotechTechnology & Innovation
Qurient announced a Science Advances study finding that Q901, its selective CDK7 inhibitor, enhances the antitumor activity of TOP1 inhibitor antibody-drug conjugates (TOP1i-ADCs). The preclinical research supports potential combination-development opportunities, but no clinical efficacy, regulatory, or financial details were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- South Korea’s exports hit record high on AI boom
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- Asia stocks rise on chipmaker gains, soft U.S. inflation; Nikkei outperforms
- We're raising our Micron price target after an incredible quarter and robust guidance
- Why is Kioxia stock rallying today?